Kornimate/medical-research-clean huggingface dataset:
wearable skin sensors to assess nocturnal scratch behavior

Conditions: Atopic Dermatitis

Summary: pilot study of flexible and wearable sensor to monitor nocturnal scratching behavior

present an advanced flexible, and wearable sensor intimately coupled to the skin that can measure the full spectrum of relevant physiological parameters associated with atopic dermatitis including scratch count, scratch duration, scratch intensity, heart rate, heart rate variability and respiratory rate.

Eligibility criteria:
inclusion criteria: * participants with mild to moderate atopic dermatitis ages 2 years or older. this will be determined by clinical diagnosis of ad according to the hanifin and rajka criteria with a baseline investigators global assessment score of mild (2) or moderate (3) * systemic therapy use (e.g. oral corticosteroid, cyclosporine, methotrexate, phototherapy) within 28 days of subject enrollment * topical corticosteroid use or topical calcineurin inhibitor use within 14 days of subject enrollment * willingness and ability to set up an infrared video camera nightly * willing to apply topical crisaborole twice daily to affected atopic dermatitis areas of the body exclusion criteria: * active skin or systemic infection * inability to operate a smartphone or video camera * active atopic dermatitis on he dorsum of the hand or suprasternal notch

Keywords: wearables atopic dermatitis scratch sensor
does treximet improve productivity and patient satisfaction due to sustained response and consistency of response?

Conditions: Workplace Migraine Treatment

Summary: researchers want to learn about work productivity after treatment of a migraine headache with your usual migraine medication as compared to your work productivity after treatment with treximet. during this research subjects will take treximet to treat 3 workday migraine attacks. for a second part of the research subjects will take their usual prescribed medication for 3 workday migraine attacks. the subjects will complete questionnaires after treating each migraine.

a subject who is identified for study participation will participate in the screening and enrollment visit which determines the migraine treatment arm to which the subject will be randomized first. the subject will have a physical exam, vital signs recorded, health and medication questions asked, questionnaires completed and a headache diary explained and dispensed to the subject. if the subject is randomized to the treximet treatment arm during the first part of the study, treximet will be dispensed for use in treating workday migraines. the subject will call the study coordinator after treating a workday migraine and will report information about the migraine to the coordinator. when the subject has treated and reported on 3 migraines, the interim visit will be scheduled. the subject will bring the study diary and treximet containers (if this was the arm the subject completed)to this visit. the subject will be asked about adverse events and medication changes as well as confirmation and review of the completed questionnaires and diaries from the prior weeks of study participation. the subject will be given new diaries and questionnaires (and treximet to use if usual prescribed triptan was the treatment in the first arm) and repeat the activities to treat 3 more workday migraines. when the subject has notified the study coordinator about treating the 3rd workday migraine in this part of the study, the subject will be scheduled for the final study visit. the subject will bring the completed migraine diaries, completed questionnaires (and treximet bottles if used during this arm) to the study visit. the subject will have the diaries and questionnaires reviewed, be asked about adverse events and medication changes and complete the final study questionnaires at this visit.

Eligibility criteria:
inclusion criteria: * episodic migraine diagnosis * age 18 or older * currently using a triptan as primary migraine monotherapy * currently employed * if of childbearing potential, willing to prevent pregnancy during study participation * able to understand and consent to study participation exclusion criteria: * younger than age 18 * not having episodic migraine diagnosis * not using a triptan as primary migraine monotherapy * not currently employed * pregnant or nursing or unwilling to prevent pregnancy during study participation * unable to understand and consent to study participation

Keywords: productivity migraine treximet triptan
dna clearance of uncomplicated trichomonas vaginalis infections in hiv negative women

Conditions: Trichomonas Vaginitis

Summary: the objective of this study is to screen treated trichomonas vaginalis (tv) positive women weekly using culture and polymerase chain reaction (pcr) to determine how long tv dna is detectable post treatment and to examine potential confounders to clearance such as bacterial vaginosis.

trichomonas vaginalis (tv), the most common sexually transmitted infection in the world, is associated with inflammation of the vagina, cervix, and urethra; low birth weight; preterm delivery; pelvic inflammatory disease; and may increase the risk of acquiring and transmitting genital herpes and hiv. repeat infections are common, ranging from 5% - 31%, and have similar health outcomes as primary infections. given the high prevalence of tv, the absence of a national screening program, the deleterious reproductive outcomes associated with tv and the potential for a tv infection to increase hiv transmission, reducing repeat tv infections is an important targeted public health approach. however, rescreening for tv should not happen until there is sufficient time for the parasites and dna to clear from the vaginal cavity after treatment. hiv negative women who attend delgado personal health center will be asked to enroll in the screening component in order to test them for tv using inpouch culture along with the standard tv screening of wet preparation. the objective of this study is to screen treated tv positive women weekly using culture and polymerase chain reaction to determine how long tv dna is detectable post treatment and to examine potential confounders to clearance such as bacterial vaginosis. the outcome of interest will be a negative pcr result indicating that tv dna has cleared.

Eligibility criteria:
inclusion criteria: * english speaking females * \>18 years old * hiv-negative * a patient at the delgado personal health center exclusion criteria: * hiv+ women

Keywords: trichomonas vaginalis
the extract of green tea on obese women: a randomized double blindness clinical trial

Conditions: Obesity

Summary: the purpose of this study is to examine whether the extract of the green tea is effective on obese women.

we conducted the pilot study in 2005. the initial findings showed the extract of green tea is benefit on obese women. the potential benefit include appetite lowing, lipid markers decreasing and regulating balance of obese related hormone peptides. so we designed this trial.

Eligibility criteria:
inclusion criteria: 1. age 16-60 years old female 2. bmi\>27㎞/m2 3. signed informed consent exclusion criteria: 1. endocrine disease, e.g. thyroid disorder, pituitary disorder, and sex gland disorder. 2. heart disease, e.g. arrhythmia, heart failure, myocardial infarction, and patient with pacemaker. 3. allergy and immunology disease. 4. high aminotransferases ( alanine, aspartate \>80 iu/l) or high serum creatinine (\>2.5 mg/dl) 5. pregnant or lactating women. 6. childbirth within 6 months. 7. stroke or otherwise unable to exercise 8. management for weight control within 3 months. 9. any other conditions deemed unsuitable for trial as evaluated by the physician-in-charge.

Keywords: obesity green tea
psa versus stn dbs for td-pd

Conditions: Parkinson Disease

Summary: the aim of this study is to compare the effectiveness of the deep brain stimulation in the posterior subthalamic area (psa) versus the subthalamic nucleus (stn) for the treatment of tremor-dominant parkinson's disease (pd) in a randomized, double-blinded, cross-over manner.

this is a randomized, double-blinded, crossover trial aiming at comparing the efficacy of psa and stn dbs in treating tremor-dominant pd. enrolled patients will undergo bilateral dbs surgery, targeting both psa and stn with single trajectory. two months post-implantation, patients enter a 4-month double-blinded crossover phase with psa and stn dbs in randomized order. after 6 months post-implantation (at the end of the crossover phase), patients enter an open-label phase during which programming parameters are not restricted until the termination of the study at 12-month follow-up.

Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic parkinson's disease * tremor-dominant subtype in the on-medication condition * modified hoehn-yahr scale of 2 to 4 in the on-medication condition * receiving regular anti-parkinsonian drugs for more than 6 weeks * good compliance and written informed consent provided exclusion criteria: * atypical parkinsonism * history of stroke, encephalitis, neuroleptic uses, mri scan with evidence of significant brain atrophy, lacunar infracts, or other conditions that might interfere with the intracranial surgery * presence of cognitive, or psychiatric or other co-morbidities (e.g., dementia, epilepsy, cranial traumatism, brain tumor, schizophrenia, severe depression or bipolar disorder, personality disorder, etc.) that might interfere with the patient's ability to complete the evaluations or to provide informed consent * presence of anatomical abnormalities in the target region * clinically significant medical history that would increase pre-/post-operative complications * other conditions considered by the investigators that might interfere with the surgery procedure, the follow-ups, and the interpretation of the data

Keywords: tremor-dominant parkinson's disease deep brain stimulation posterior subthalamic area subthalamic nucleus
neutrophil to lymphocyte ratio in inflammatory bowel disease

Conditions: Inflammatory Bowel Diseases

Summary: detection of inflammatory bowel disease activity by using new measure : neutrophil to lymphocyte ratio

inflammatory bowel disease (ibd) has been a global healthcare problem with a sustained increasing incidence. it includes two major forms, crohn's disease (cd) and ulcerative colitis (uc), which are distinct chronic bowel-relapsing inflammatory disorders (gharagozloo et al., 2015). ulcerative colitis (uc) is limitd to mucosa and cause continuous bowel inflammation (celikbilek et al., 2013) while crohn disease is more complex because of its transmural inflammation and it is characterized by skip lesions, which are diseased sections of bowel next to uninvolved areas(nishijima david l; wisner, david h; holmes, james f, 2016). the prevalence of ibd is highest in the second to third decade of life with another peak in the 60-70- year-old group.(silva et al., 2016) non-invasive tests, such as c reactive protein (crp), erythrocyte sedimentation rate (esr) and white blood cells (wbc) are therefore being increasingly recognized as important markers for initial diagnosis and disease activity detection.(gao et al., 2015) in recent years, the neutrophil-to-lymphocyte ratio (nlr), calculated as total neutrophil count divided by total lymphocyte count, nlr represents two different immune pathways and can be easily derived directly from a standard blood test..(argeny et al., 2018)

Eligibility criteria:
inclusion criteria: * patients with inflammatory bowel disease, diagnosed by endoscopy, clinical , biochemical correlation and histopathological biopsy exclusion criteria: * patients have : * appendicitis * sigmoid diverticular disease * infectious colitis * patients known to have cancer colon

Keywords: neutrophil to lymphocyte ratio
a four week, open-label study of azithromycin ophthalmic solution, 1% (p08641)

Conditions: Posterior Blepharoconjunctivitis

Summary: one objective of this study is to determine the levels of markers of inflammation on the eyelid margin of subjects with blepharoconjunctivitis and compare them with those of healthy volunteers. another objective is to determine in subjects with blepharoconjunctivitis the effect of azithromycin ophthalmic solution, 1 % on markers of inflammation of lid margins and conjunctivae and on signs and symptoms of blepharoconjunctivitis.


Eligibility criteria:
inclusion criteria: * have a current diagnosis of posterior blepharoconjunctivitis in both eyes (except for healthy volunteers) * have a best corrected visual acuity (bcva), using corrective lenses if necessary, in both eyes of at least +0.7 logmar * if female, are non-pregnant or non-lactating exclusion criteria: * have anterior blepharitis * have lid structural abnormalities * have had penetrating intraocular surgery in the past 90 days or require penetrating intraocular surgery during the study * unable to withhold the use of contact lenses within 3 days prior to visit 1 during the study * have been diagnosed with ongoing glaucoma * have a serious medical condition which could confound study assessments
a long-term extension study evaluating a one-month dosing regimen of degarelix in prostate cancer requiring androgen ablation therapy

Conditions: Prostate Cancer

Summary: participants who completed the fe200486 cs21 study (nct00295750) could enter the fe200486 cs21a study. the study continued until all non-discontinued participants had received treatment for at least 5 years.


Eligibility criteria:
inclusion/exclusion criteria: * patients with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated. * signed informed consent * the patients must have completed the fe 200486 cs21 study.

Keywords: degarelix prostate cancer
melatonin replacement therapy in pinealectomized patients

Conditions: Pineal Tumor

Summary: this is an open-label, single-arm, single-center, proof-of-concept study to assess the effects of melatonin on cardiac autonomic activity in melatonin non-proficient pinealectomized patients.

this is an open-label, single-arm, single-center, proof-of-concept study to assess the effects of melatonin on cardiac autonomic activity in melatonin non-proficient pinealectomized patients. the study consists of a screening period, followed by a 3-month melatonin treatment period, and a 6-month washout follow-up period. adverse events were monitored with respect to seriousness, intensity, relationship to treatment, action taken and outcome of the event.

Eligibility criteria:
inclusion criteria: * patients with pinealectomy and all of the following criteria were considered for admission to the clinical trial: * children, adolescents and young adults 0 months to 25 years of age; * signed written informed consent (patient or his/her parents/legal guardian); * willing and able to complete the clinical trial procedures, as described in the protocol * no recurring tumor after pinealectomy and subsequent chemotherapy * absence of circulating melatonin evaluated by salivary melatonin elisa assay exclusion criteria: * patients with cardiac arrhythmias * potentially non-compliant subjects judged by the investigator to be unsuitable for the study

Keywords: melatonin pinealectomy cardiac autonomic system heart rate variability
effect of virtual reality glasses application on surgical fear and anxiety

Conditions: Virtual Reality; Fear; Anxiety State; Surgery

Summary: purpose and type of research:this study will be conducted to examine the effect of virtual reality glasses on surgical fear and anxiety in patients scheduled for cardiovascular surgery. the study is a randomized controlled experimental research. method:the population of the research was approximately 2900 patients who underwent cardiovascular surgery in a year at dr. siyami ersek thoracic and cardiovascular surgery education research hospital. the sample size of the study was calculated using the g\*power software program.the study will be completed with 60 people by taking 30 people into the experimental and control groups.data will be collected with a personal information form, surgical fear scale and state anxiety scale. hypothesis of the research: h1: application of virtual reality glasses reduces surgical fear in patients planned for cardiovascular surgery. h2: application of virtual reality glasses reduces anxiety in patients scheduled for cardiovascular surgery.


Eligibility criteria:
inclusion criteria: * 18 years and over, * those who will undergo open heart surgery, * those who have not had cardiovascular surgery before, * no communication problems, * is conscious and able to answer questions and does not have any disorder/disease that affects decision-making ability (dementia, alzheimer's, etc.), * does not have a psychiatric disease such as anxiety disorder, panic attack, depression, * individuals who do not receive psychiatric treatment such as antipsychotics/anxiolytics will be included in the study. exclusion criteria: * being under the age of 18, * not having open heart surgery, * those who have previously undergone cardiovascular surgery, * having communication problems, * those who are unconscious and unable to answer questions having any disorder/disease that affects decision-making ability (dementia, alzheimer's, etc.), * having a psychiatric disease such as anxiety disorder, panic attack, depression, * individuals receiving psychiatric treatment such as antipsychotic/anxiolytic will not be included in the study.

Keywords: heart surgery surgical fear anxiety virtual reality
retrospective non-interventional study of stiripentol use in dravet patients in the usa

Conditions: Dravet Syndrome

Summary: the present study aims to collect data regarding the history of the disease, previous and current treatments, and the clinical status of dravet patients during the 3 months prior to stiripentol initiation, the first 3 months on stiripentol and the last 3 months on stiripentol (irrespective of stiripentol discontinuation).


Eligibility criteria:
inclusion criteria: * patients diagnosed with dravet syndrome * treated with stiripentol for a minimum of 3 months in routine practice exclusion criteria: * na
covid-19 convalescent plasma therapy

Conditions: SARS-CoV-2 Infection; COVID-19 Infection

Summary: this study is an open-label trial in which hospitalized patients with risk factors of severe coronavirus disease 2019 \[covid-19\] will be receive treatment with convalescent plasma (≤ 15 days from symptoms start).


Eligibility criteria:
inclusion criteria: * 18 years and older * presence of risk factors of severe covid 19 diagnosed by quantitative polymerase chain reaction by reverse transcription (rt-qpcr) * patients with no more than 15 days from the onset of symptoms * signed informed consent exclusion criteria: * severely ill patients admitted directly to the icu. * need for mechanical ventilation at the time of hospital admission, regardless of the time of clinical evolution. * history of previous hypersensitivity to plasma transfusions. * history of immunoglobulin a (iga) deficiency * pregnancy

Keywords: sars-cov-2 infection convalescent plasma
vitamin k2 and recovery from exercise

Conditions: Inflammation; Oxidative Stress; Vitamin K; Exercise; Strength; Recovery

Summary: the aim of the current study, therefore, is to investigate the effects of vitamin k2 supplementation on the physiological responses to an acute bout of resistance exercise.


Eligibility criteria:
inclusion criteria: * participant is able and willing to sign the informed consent from * no plans to change lifestyle (activity and nutrition) during the study period * older group (n=40): 65 years of age or older. * younger group (n=40): aged 18-40 years exclusion criteria: * not currently, or in the last year, participating in more than 1h per week of vigorous aerobic physical activity or any resistance exercise * bmi \> 30 kg/m2 * diabetes * severe cardiovascular disease * seizure disorders * liver disease * uncontrolled hypertension (\>150/90mmhg at baseline measurement) * cancer or cancer that has been in remission \<5 years * ambulatory impairments which would limit ability to perform assessments of muscle function * dementia * currently taking vitamin k2 supplements * currently taking vitamin k antagonists/anticoagulants (e.g. warfarin) * current smoking * history of drug abuse * taking medication known to affect muscle (e.g. steroids).
effects of pranayama breathing technique in patients with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: it will be randomized controlled trial. the research will be conducted at bahawal victoria hospital bahawalpur and civil hospital bahawalpur. we take 60 patients (epitool), patients will be allocated randomly in two groups. group a will get conventional medical treatment and group b will get both conventional medical treatment and pranayama breathing exercise. both gender of age group 30 to 55, patient with diagnosed chronic obstructive pulmonary disease ,moderate to severe chronic obstructive pulmonary disease with productive cough, shortness of breathe and no surgical procedure performed will be included in this study. and patients of lung surgery, lung cancer, above 70 years age, with open wound, cardiovascular issues, and neurological issues will be excluded. yoga exercise pranayama, 6 min walk test, ipaq- quality of life and vsaq-exercise capacity will be used as tools. data will be analyzed on spss 21.

it will be randomized controlled trial. after approval of synopsis the research will be conducted at bahawal victoria hospital bahawalpur and sadiq abbasi hospital bahawalpur. written informed consent will be obtained. we take 60 patients (epitool), patients will be allocated randomly in two groups. group a and group b. group a will get conventional medical treatment and group b will get both conventional medical treatment and pranayama breathing exercise. both gender of age group 30 to 55, patient with diagnosed copd, moderate to severe copd with productive cough, sob and no surgical procedure performed will be included in this study. and patients of lung surgery, lung cancer, above 70 years age, with open wound, cardiovascular issues, and neurological issues will be excluded. yoga exercise pranayama, 6 min walk test, ipaq- quality of life and vsaq-exercise capacity will be used as tools. data will be analyzed on spss 21.

Eligibility criteria:
inclusion criteria: * both gender of age group 30 to 55 * patient with diagnosed copd. * moderate to severe copd. * patient with productive cough and sob. * no surgical procedure perform. exclusion criteria: * patient of lung surgery * lung cancer patient * patient above 70 years age. * patient with open wound. * patient with cardiovascular issues

Keywords: pranayama copd dyspnea exercise tolerance